Wall Street analysts predict that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings of ($0.22) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Evoke Pharma’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.18). Evoke Pharma posted earnings per share of ($0.18) in the same quarter last year, which would indicate a negative year over year growth rate of 22.2%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.

On average, analysts expect that Evoke Pharma will report full year earnings of ($1.00) per share for the current year, with EPS estimates ranging from ($1.03) to ($0.96). For the next fiscal year, analysts anticipate that the firm will post earnings of $0.09 per share, with EPS estimates ranging from ($0.54) to $1.16. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13). During the same quarter in the previous year, the business posted ($0.29) earnings per share.

EVOK has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a research note on Monday, September 18th. FBR & Co reissued a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research note on Monday, October 30th. Zacks Investment Research raised Evoke Pharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 12th. B. Riley reissued a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research note on Wednesday, November 15th. Finally, Northland Securities reissued a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research note on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Evoke Pharma has a consensus rating of “Buy” and a consensus price target of $9.00.

Shares of Evoke Pharma (NASDAQ EVOK) traded up $0.04 during trading hours on Friday, reaching $2.69. The company’s stock had a trading volume of 82,106 shares, compared to its average volume of 401,574. Evoke Pharma has a 52-week low of $1.42 and a 52-week high of $4.55.

A hedge fund recently raised its stake in Evoke Pharma stock. Vanguard Group Inc. increased its position in Evoke Pharma Inc (NASDAQ:EVOK) by 15.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 523,650 shares of the specialty pharmaceutical company’s stock after buying an additional 68,544 shares during the quarter. Vanguard Group Inc. owned about 3.40% of Evoke Pharma worth $1,341,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 13.64% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/12/evoke-pharma-inc-evok-expected-to-announce-earnings-of-0-22-per-share.html.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Stock Ratings for Evoke Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc and related stocks with our FREE daily email newsletter.